Business Description
Active Biotech AB
SIC : 2836
ISIN : SE0029278555
Total Employee Number:
5Compare
Compare
Traded in other countries / regions
ACTI.SwedenBTP.Germany0GQU.UK IPO Date
2000-02-28Description
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 25.3 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30.3 | |||||
3-Year EPS without NRI Growth Rate | 27.9 | |||||
3-Year FCF Growth Rate | 31.8 | |||||
3-Year Book Growth Rate | -20.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.63 | |||||
9-Day RSI | 19.62 | |||||
14-Day RSI | 24.12 | |||||
3-1 Month Momentum % | -11.43 | |||||
6-1 Month Momentum % | 25.97 | |||||
12-1 Month Momentum % | -60.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.34 | |||||
Quick Ratio | 4.34 | |||||
Cash Ratio | 4.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.4 | |||||
Shareholder Yield % | 4.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -108.38 | |||||
ROA % | -77.77 | |||||
ROIC % | -252.57 | |||||
3-Year ROIIC % | -639.16 | |||||
ROC (Joel Greenblatt) % | -1744.37 | |||||
ROCE % | -108.28 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.91 | |||||
Price-to-Tangible-Book | 2.93 | |||||
EV-to-EBIT | -1.31 | |||||
EV-to-EBITDA | -1.31 | |||||
EV-to-FCF | -1.63 | |||||
| Price-to-Net-Current-Asset-Value | 3.06 | |||||
| Price-to-Net-Cash | 3.25 | |||||
Earnings Yield (Greenblatt) % | -75.99 | |||||
FCF Yield % | -29.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Active Biotech AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.625 | ||
| Beta | 0.4684 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.62 | ||
| Volatility % | 68.47 | ||
| 14-Day RSI | 24.12 | ||
| 14-Day ATR (kr) | 0.219371 | ||
| 20-Day SMA (kr) | 4.908 | ||
| 12-1 Month Momentum % | -60.36 | ||
| 52-Week Range (kr) | 3.7 - 14.076052 | ||
| Shares Outstanding (Mil) | 26.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Active Biotech AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Active Biotech AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 148 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 49 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 5.16 (-0.96%) | ||
| 0.01:1 Stock Split | 2026-06-03 | 6.08 (+1.33%) | ||
| General meeting for 2026 | 2026-05-20 17:00 | 7.48 (-5.08%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.00 (-0.66%) | ||
| Annual report for 2025 | 2026-04-01 | 5.49 (+17.06%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 3.86 (-0.52%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 6.28 (-1.98%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 14.20 (-3.35%) |
Show
Entries
Active Biotech AB Frequently Asked Questions
What is Active Biotech AB(OSTO:ACTI)'s stock price today?
The current price of OSTO:ACTI is kr4.10. The 52 week high of OSTO:ACTI is kr14.08 and 52 week low is kr3.70.
When is next earnings date of Active Biotech AB(OSTO:ACTI)?
The next earnings date of Active Biotech AB(OSTO:ACTI) is 2026-11-05.
Does Active Biotech AB(OSTO:ACTI) pay dividends? If so, how much?
Active Biotech AB(OSTO:ACTI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers